SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 6, 2008--XenoPort, Inc.
(Nasdaq:XNPT) announced today that it will provide access via the
World Wide Web to its presentations at the following upcoming
- Rodman & Renshaw 10th Annual Healthcare Conference
Tuesday, November 11 at 12:25 p.m. Eastern Time
- Credit Suisse 2008 Healthcare Conference
Thursday, November 13 at 10:30 a.m. Eastern Time
To access the live presentations via the Web, please go to
www.XenoPort.com. Please connect to the Web site at least 15 minutes
prior to the live presentation to ensure adequate time for any
software downloads that may be necessary to listen to the Webcast.
A replay of each Webcast can be accessed for a minimum of one week
and will be available approximately 24 hours after the respective live
XenoPort, Inc. is a biopharmaceutical company focused on
developing a portfolio of internally discovered product candidates
that utilize the body's natural nutrient transport mechanisms to
improve the therapeutic benefits of existing drugs. XenoPort is
developing its lead product candidate in partnership with Astellas
Pharma Inc. and GlaxoSmithKline. GlaxoSmithKline has filed with the
U.S. Food and Drug Administration a new drug application for this
product candidate, known as Solzira(TM) in the U.S., for the treatment
of restless legs syndrome. XenoPort's product candidates are also
being studied for the potential treatment of gastroesophageal reflux
disease, migraine headaches, neuropathic pain, spasticity related to
spinal chord injury, acute back spasms and Parkinson's disease.
To learn more about XenoPort, please visit the Web site at
XenoPort is a registered trademark
Solzira is a U.S. trademark of GSK.
CONTACT: XenoPort, Inc.
Jackie Cossmon, 408-616-7220
SOURCE: XenoPort, Inc.